Neurodegenerative diseases (NDs) are a wide class of disorders of the central nervous system (CNS) with still unknown etiology. Several factors were hypothesized to be involved in the pathogenesis of these diseases including genetic and environmental factors. Many of these diseases show a sex prevalence and sex steroids where shown to have a role in the progression of specific forms of neurodegeneration. Estrogens were reported to be neuroprotective though their action on cognate nuclear and membrane receptors, while adverse effects of male hormones have been described on neuronal cells, although some data also suggest neuroprotective activities. The response of the CNS to sex steroids is a complex and integrated process that depends on: i.) the type and amount of the cognate steroid receptor; ii.) the target cell-type, either neurons, glia or microglia. Moreover, the levels of sex steroids in the CNS fluctuate due to gonadal activities and to local metabolism and synthesis. Importantly, biochemical processes involved in the pathogenesis of NDs are increasingly being recognized different among the two sexes and to be influenced by sex steroids. The aim of this review is to present current state-of-the-art understanding on the potential role of sex steroids and their receptors on the onset and progression of major neurodegenerative disorders, namely Alzheimer's disease, Parkinson's diseases, Amyotrophic Lateral Sclerosis and the peculiar motoneuron disease Spinal and Bulbar Muscular Atrophy, in which hormonal therapy is potentially useful as disease modifier.

The role of sex and sex Hormones in Neurodegenerative Diseases / E. Vegeto, A. Villa, S. Della Torre, V. Crippa, P. Rusmini, R. Cristofani, M. Galbiati, A. Maggi, A. Poletti. - In: ENDOCRINE REVIEWS. - ISSN 0163-769X. - 41:2(2020 Apr), pp. 273-319.

The role of sex and sex Hormones in Neurodegenerative Diseases

E. Vegeto
Primo
;
A. Villa
Secondo
;
S. Della Torre;V. Crippa;P. Rusmini;R. Cristofani;M. Galbiati;A. Maggi
Penultimo
;
A. Poletti
Ultimo
2020

Abstract

Neurodegenerative diseases (NDs) are a wide class of disorders of the central nervous system (CNS) with still unknown etiology. Several factors were hypothesized to be involved in the pathogenesis of these diseases including genetic and environmental factors. Many of these diseases show a sex prevalence and sex steroids where shown to have a role in the progression of specific forms of neurodegeneration. Estrogens were reported to be neuroprotective though their action on cognate nuclear and membrane receptors, while adverse effects of male hormones have been described on neuronal cells, although some data also suggest neuroprotective activities. The response of the CNS to sex steroids is a complex and integrated process that depends on: i.) the type and amount of the cognate steroid receptor; ii.) the target cell-type, either neurons, glia or microglia. Moreover, the levels of sex steroids in the CNS fluctuate due to gonadal activities and to local metabolism and synthesis. Importantly, biochemical processes involved in the pathogenesis of NDs are increasingly being recognized different among the two sexes and to be influenced by sex steroids. The aim of this review is to present current state-of-the-art understanding on the potential role of sex steroids and their receptors on the onset and progression of major neurodegenerative disorders, namely Alzheimer's disease, Parkinson's diseases, Amyotrophic Lateral Sclerosis and the peculiar motoneuron disease Spinal and Bulbar Muscular Atrophy, in which hormonal therapy is potentially useful as disease modifier.
Alzheimer’s disease; Amyotrophic Lateral Sclerosis; Parkinson’s Disease; Sex Hormones; Spinal and Bulbar Muscular Atrophy
Settore BIO/13 - Biologia Applicata
Settore BIO/09 - Fisiologia
Settore BIO/14 - Farmacologia
Settore BIO/10 - Biochimica
   Imaging of Neuroinflammation in Neurodegenerative Diseases
   INMIND
   EUROPEAN COMMISSION
   FP7
   278850

   RAN translation of normal and expanded nucleotide repeat containing transcripts to neurotoxic polypetides in neurodegenerative diseases
   No RAn for old man
   FONDAZIONE CARIPLO
   2014-0686

   Extracellular vescicles in the pathogenesis of frontotemporal dementia
   FONDAZIONE CARIPLO
   2017-0747

   Motor neuron degeneration in Spinal and Bulbar Muscular Atrophy: molecular approaches to counteract mutant androgen receptor neurotoxicity
   FONDAZIONE TELETHON ETS
   GGP14039

   Upregulation of HSPB8 as potential therapeutic approach in familial and sporadic ALS
   ALS_HSPB8
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA
   ALS_HSPB8

   Membrane-less organelle pathology in ALS: identification of causes and rescuing factors (MLOMALS)
   MLOMALS
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA

   Targeting RAN translation in ALS (Target-RAN)
   Target-RAN
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA

   Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial (Co-ALS)
   Co-ALS
   AGENZIA ITALIANA DEL FARMACO - AIFA
   AIFA-2016-02364678

   From RNA to Protein toxicity in motorneuron diseases
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2015LFPNMN_006

   From RNA to Protein toxicity in motorneuron diseases
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2015LFPNMN_001

   Stress granules and proteostasis in motor neurons: towards a mechanistic understanding of ALS (CureALS)
   CureALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO

   The interplay between the “rna/protein quality control system” and “exosomes” as a spreading mechanism in amyotrophic lateral sclerosis (EX_ALS)
   EX_ALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2017F2A2C5_001

   Translating molecular mechanisms into ALS risk and patient's well-being
   TRANS-ALS
   FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA
   2015-0023
apr-2020
23-set-2019
Centro Interdipartimentale di Eccellenza per le Malattie Neurodegenerative CEND
Article (author)
File in questo prodotto:
File Dimensione Formato  
bnz005.pdf

Open Access dal 01/01/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 4.21 MB
Formato Adobe PDF
4.21 MB Adobe PDF Visualizza/Apri
bnz005.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 18.73 MB
Formato Adobe PDF
18.73 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/676978
Citazioni
  • ???jsp.display-item.citation.pmc??? 59
  • Scopus 137
  • ???jsp.display-item.citation.isi??? 123
social impact